Company profile
Haemonetics Corporation
NYSE: HAE · Healthcare · Medical - Devices
#133 of 1,418 Healthcare companies by revenue38th-percentile growth
EA Score
79B+FH 87DQ 72GM 59SS 93
v0.1 · 65/100 weight · provisional
↑ Piotroski F, listing tenure · ↓ revenue growth (YoY), 3-yr revenue growth
Methodology →Revenue TTM
$1.3B
Rev growth YoY (TTM)
-2.0%
Net income (FY)
$97.3M
Employees
3,009
as of 2026-08-08
Market cap
$4.0B
as of 2026-08-08
Financials — latest annual
SEC EDGAR · USD-normalizedConceptUSDNativeFY
Revenue$1.3B$1.3B2026
Net income$97.3M$97.3M2026
Operating income$156.7M$156.7M2026
Total assets$2.4B$2.4B2026
Equity$796.3M$796.3M2026
Revenue trend
FY2021 – FY2026 · USD
FY21
FY21
FY21
FY24
FY24
FY24
FY25
FY26
Revenue by segment
Filed disclosures · FY2026
By product
Hospital27%
Plasma24%
Hemostasis Management, Hospital17%
Interventional Technologies, Hospital11%
Blood Center10%
Apheresis, Blood Center10%
By geography
UNITED STATES74%
Europe14%
Asia7%
JAPAN5%
Other Country or Region1%
The read
What is Haemonetics Corporation’s revenue?
Haemonetics Corporation booked $1.3B in FY2026 revenue, contracting 2.0% year over year — slower than 62% of Healthcare companies we track, at a 7.3% net margin.
Peers · Healthcare
Penumbra, Inc.83B+Halozyme Therapeutics, Inc.85ACONMED Corporation83B+HealthEquity, Inc.83B+Phibro Animal Health Corporation76B+Progyny, Inc.71BNeighbors
Suffolk →Key facts
CEOChristopher A. Simon
SectorHealthcare
IndustryMedical - Devices
HeadquartersBoston, MA
ExchangeNYSE: HAE
Employees3,009
IPO date1991-05-10
Financials: SEC EDGAR (XBRL), USD-normalized per IAS 21 · TTM/quarterly + segments: FMP from filed disclosures · Filings: EDGAR submissions. County headcount and EA Score are in progress — see docs/DATA_GAPS.md.